<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137773">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01785381</url>
  </required_header>
  <id_info>
    <org_study_id>IRIS recherche 2012820690007</org_study_id>
    <nct_id>NCT01785381</nct_id>
  </id_info>
  <brief_title>RCT: Added Value of Coordinator for the Management of Hip Fracture Patients</brief_title>
  <official_title>Randomized Controlled Trial: Added Value of Coordinator for the Management of Hip Fracture Patients in a Network of Public Hospitals in Brussels.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Saint Pierre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Saint Pierre</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Hip fracture due to osteoporosis is associated with an extremely high
      mortality morbidity and loss of quality of life. The risk of future fracture after a first
      hip fracture is increased. Several studies reported that patients who suffered from a
      fracture are not optimally treated and do not receive osteoporosis treatment after the first
      fracture episode.

      Aim: To evaluate whether a coordinator increases the optimal management of osteoporotic
      fracture patients and hip fracture patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Material and methods: Population: Identification in the &quot;IRIS public hospital network of all
      patients above 50 years&quot; who suffer from hip fracture. Exclusion of those due to high energy
      fractures and due to known cancer.

      First observational phase of treatment followed by randomized controlled trials of 2 years.

      Intervention (RCT): Added value of a coordinator. Measured outcomes : A. New fractures.  B.
      A score of optimal management of osteoporosis.

      Definition of the score and management: 1. Realization of a bone density measurement. 2.
      Identification of secondary osteoporosis. 3. Identification of risk factors and calculation
      of the probability of a future fracture using FRAX score. 4. Attempt to correct risk factors
      of osteoporosis when possible. 5. Prevention of falls. 6. Prescription of calcium and
      vitamin D. 7. Prescription of a medical osteoporosis treatment. 8. Report to the general
      practitioner.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>A score of optimal management of osteoporosis.</measure>
    <time_frame>3-6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Definition of the score and management: 1. Realization of a bone density measurement. 2. Identification of secondary osteoporosis. 3. Identification of risk factors and calculation of the probability of a future fracture using FRAX score. 4. Attempt to correct risk factors of osteoporosis when possible. 5. Prevention of falls. 6. Prescription of calcium and vitamin D. 7. Prescription of a medical osteoporosis treatment. 8. Report to the general practitioner.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New fractures.</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>usual care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Added value of coordinator</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Added value of coordinator</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Added value of coordinator</intervention_name>
    <description>Added value of coordinator</description>
    <arm_group_label>Added value of coordinator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Identification in the &quot;IRIS public hospital network of all patients above 50 years&quot;
             who suffer from hip fracture.

        Exclusion Criteria:

          -  Exclusion of those due to high energy fractures and due to known cancer.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Katty Renard, RN</last_name>
    <phone>+32 2 535 48 56</phone>
    <email>katty_renard@stpierre-bru.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRIS Hospitals</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Innocent Nyaruhirira, MD</last_name>
      <phone>+32 485 93 25 44</phone>
      <email>innocent_nyaruhirira@stpierre-bru.be</email>
    </contact>
    <investigator>
      <last_name>Serge Rozenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 5, 2013</lastchanged_date>
  <firstreceived_date>February 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Saint Pierre</investigator_affiliation>
    <investigator_full_name>Nyaruhirira Innocent</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Osteoporosis, hip fracture, fractures, Bone density</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
